Insider · CIK 0001707648

TOMBESI PAOLO

Reports to the SEC for 3 companies · BRIDGEWATER, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001707648

Forms 4 and 5

Insider transactions

27 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-08-17	Turning Point Therapeutics, Inc.D Disposition to Issuer	EVP & Chief Financial Officer	DDisposition to Issuer	−29.8K sh	$76.00	−$2.26M	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	EVP & Chief Financial Officer	DDisposition to Issuer	−61.2K sh	—	—	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	EVP & Chief Financial Officer	DDisposition to Issuer	−58.6K sh	—	—	0
2022-07-27	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−1,183 sh	$74.94	−$88.7K	28,700
2022-02-09	Turning Point Therapeutics, Inc.A Award	EVP & Chief Financial Officer	AAward	+16.3K sh	—	—	29,883
2022-02-09	Turning Point Therapeutics, Inc.Stock Option (right to buy)A Award	EVP & Chief Financial Officer	AAward	+58.6K sh	—	—	58,600
2021-07-26	Turning Point Therapeutics, Inc.A Award	EVP & Chief Financial Officer	AAward	+13.6K sh	—	—	13,600
2021-07-26	Turning Point Therapeutics, Inc.Stock Option (right to buy)A Award	EVP & Chief Financial Officer	AAward	+61.2K sh	—	—	61,200
2021-02-04	Epizyme, Inc.S Sale	Chief Financial Officer	SSale	−1,021 sh	$11.21	−$11.4K	53,465
2021-02-01	Epizyme, Inc.A Award	Chief Financial Officer	AAward	+26K sh	—	—	54,486
2021-02-01	Epizyme, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+124K sh	—	—	124,239
2020-08-20	Epizyme, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−2,091 sh	$12.55	−$26.2K	26,906
2020-08-19	Epizyme, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,055 sh	—	—	28,997
2020-08-19	Epizyme, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,055 sh	—	—	21,162
2020-06-26	Epizyme, Inc.S Sale	Chief Financial Officer	SSale	−1,805 sh	$16.15	−$29.2K	21,942
2020-06-25	Epizyme, Inc.A Award	Chief Financial Officer	AAward	+6,000 sh	—	—	23,747
2020-03-25	Epizyme, Inc.S Sale	Chief Financial Officer	SSale	−1,243 sh	$15.28	−$19K	15,437
2020-03-24	Epizyme, Inc.A Award	Chief Financial Officer	AAward	+1,690 sh	—	—	16,680
2020-03-24	Epizyme, Inc.A Award	Chief Financial Officer	AAward	+4,000 sh	—	—	17,747
2020-02-03	Epizyme, Inc.A Award	Chief Financial Officer	AAward	+11.7K sh	—	—	14,990
2020-02-03	Epizyme, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+56.2K sh	—	—	56,213
2020-01-23	Epizyme, Inc.A Award	Chief Financial Officer	AAward	+5,000 sh	—	—	5,000
2020-01-23	Epizyme, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−1,698 sh	$26.72	−$45.4K	3,302
2019-08-19	Epizyme, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+132K sh	—	—	132,225
2019-08-19	Epizyme, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+28.2K sh	—	—	28,217
2019-01-03	INSMINSMED Inc · Stock OptionA Award	Chief Financial Officer	AAward	+120K sh	—	—	120,280
2017-06-01	INSMINSMED Inc · Stock OptionA Award	Chief Financial Officer	AAward	+127K sh	—	—	127,160

Recent filings

Accepted (ET)
Aug 174
TOMBESI PAOLO0001209191-22-046272
SEC(opens sec.gov)
Jul 294
TOMBESI PAOLO0001209191-22-043510
SEC(opens sec.gov)
Feb 114
TOMBESI PAOLO0001209191-22-008985
SEC(opens sec.gov)
Jul 274
TOMBESI PAOLO0001209191-21-048337
SEC(opens sec.gov)
Feb 54
TOMBESI PAOLO0000899243-21-005042
SEC(opens sec.gov)
Feb 24
TOMBESI PAOLO0000899243-21-004516
SEC(opens sec.gov)
Aug 214
TOMBESI PAOLO0000899243-20-023197
SEC(opens sec.gov)
Jun 304
TOMBESI PAOLO0000899243-20-017902
SEC(opens sec.gov)
Jun 304/A
TOMBESI PAOLO0000899243-20-017854
SEC(opens sec.gov)
Mar 264
TOMBESI PAOLO0000899243-20-009607
SEC(opens sec.gov)
Feb 54
TOMBESI PAOLO0000899243-20-003366
SEC(opens sec.gov)

Companies

Address

10 FINDERNE AVENUE BUILDING 10

BRIDGEWATER, NJ, 08807